PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15784655-3 2005 YC-1 inhibited the ability of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in a dose-dependent manner to induce proliferation, migration, and tube formation in human umbilical vascular endothelial cells; these outcomes were evaluated using [3H]thymidine incorporation, transwell chamber, and Matrigel-coated slide assays, respectively. Thymidine 283-292 vascular endothelial growth factor A Homo sapiens 30-64 18032585-3 2008 HMVECs, cultured in low serum, responded to VEGF with an increase in [(3)H]thymidine incorporation that was inhibited by TSPs and was accompanied by decreases in the phosphorylation of Akt and MAPK, without an increase in apoptosis. Thymidine 75-84 vascular endothelial growth factor A Homo sapiens 44-48 18032585-4 2008 RAP, an inhibitor of the low-density lipoprotein (LDL) family of endocytic receptors, and blocking antibodies to VLDLR were as effective as TSPs in the inhibition of thymidine uptake in response to VEGF, and the effects of these agents were not additive. Thymidine 166-175 vascular endothelial growth factor A Homo sapiens 198-202 15784655-3 2005 YC-1 inhibited the ability of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in a dose-dependent manner to induce proliferation, migration, and tube formation in human umbilical vascular endothelial cells; these outcomes were evaluated using [3H]thymidine incorporation, transwell chamber, and Matrigel-coated slide assays, respectively. Thymidine 283-292 vascular endothelial growth factor A Homo sapiens 66-70 15937404-4 2005 Our findings showed that M475271 pretreatment resulted in a significant inhibition of VEGF-induced HUVEC proliferation, [(3)H]thymidine incorporation, and migration. Thymidine 126-135 vascular endothelial growth factor A Homo sapiens 86-90 15506488-4 2004 RESULTS: [3H] thymidine incorporation into TM cells was promoted by 10 and 100 ng/ml of PDGF, IGF-1, and FGF2 after 24 and 48 hours, whereas 1, 10, and 100 ng/ml of VEGF restrained cell proliferation after 48 hours. Thymidine 14-23 vascular endothelial growth factor A Homo sapiens 165-169 12620928-9 2003 VEGF increased podocyte [(3)H]-thymidine incorporation (3,349 +/- 283 cpm, control 2,364 +/- 301 cpm, P < 0.05) and cell number (4.5 +/- 0.7 x 10(4)/ml, control 2.6 +/- 0.5 x 10(4)/ml, P < 0.05) and decreased cytotoxicity (5.9 +/- 0.7%, control 12 +/- 3%, P < 0.05), whereas a monoclonal antibody to VEGF increased cytotoxicity. Thymidine 31-40 vascular endothelial growth factor A Homo sapiens 0-4 11316566-7 2001 VEGF(165) proved to have a radioprotective effect as ECs" thymidine uptake, after radiation doses of 2, 6, and 10 Gy, was increased by 1.5-, 2-, and 4-fold, respectively, in the presence of 10 ng/ml of VEGF(165) (p < 0.05 vs. LacZ). Thymidine 58-67 vascular endothelial growth factor A Homo sapiens 0-4 12483548-4 2002 METHODS: Endothelial cell proliferation was assayed by (3)H-thymidine incorporation in response to VEGF-A +/- ZM323881. Thymidine 60-69 vascular endothelial growth factor A Homo sapiens 99-105 11834522-3 2002 The addition of recombinant vascular endothelial growth factor (50 ng/mL) or epidermal growth factor (50 ng/mL) significantly increased thymidine incorporation and c-fos promoter activity, whereas TNF-alpha (5 ng/mL) attenuated these effects in human or bovine aortic endothelial cells. Thymidine 136-145 vascular endothelial growth factor A Homo sapiens 28-62 11312104-4 2001 The role of these channels in VEGF-induced proliferation (cell count, [3H]thymidine incorporation) was studied using the specific inhibitor iberiotoxin. Thymidine 74-83 vascular endothelial growth factor A Homo sapiens 30-34 11352660-3 2001 We assessed the effect of exogenous VEGF on BeWo cell proliferation by [3H]thymidine incorporation. Thymidine 75-84 vascular endothelial growth factor A Homo sapiens 36-40 11026652-10 2000 This conditioned medium increased [3H]thymidine incorporation by HUVECs, which was significantly inhibited by co-transfection of sFLT-1 gene with VEGF gene. Thymidine 38-47 vascular endothelial growth factor A Homo sapiens 146-150 11026643-7 2000 Thymidine incorporation into human vascular endothelial cells was significantly increased by incubation with the conditioned medium from AAV-VEGF-transduced myocytes. Thymidine 0-9 vascular endothelial growth factor A Homo sapiens 141-145 11026643-8 2000 This increased thymidine uptake was significantly inhibited by anti-VEGF antibody. Thymidine 15-24 vascular endothelial growth factor A Homo sapiens 68-72 11103787-5 2000 We show that thymidine induces oxidative stress in TP-overexpressing carcinoma cells, promoting secretion of the stress-induced angiogenic factors vascular endothelial growth factor and interleukin-8, and inducing matrix metalloproteinase-1. Thymidine 13-22 vascular endothelial growth factor A Homo sapiens 147-181 10671553-4 2000 By signaling through KDR, VEGF promoted the tyrosine phosphorylation of focal adhesion kinase, induced activation of Akt, protein kinase Cepsilon (PKCepsilon), mitogen-activated protein kinase (MAPK), and promoted thymidine incorporation into DNA. Thymidine 214-223 vascular endothelial growth factor A Homo sapiens 26-30 10864579-5 2000 VEGF(165) induced a dose-responsive increase in (3)H-thymidine incorporation (25 ng/ml VEGF(165) : 2.3-fold increase; 50 ng/ml : 3.8-fold; 100 ng/ml : 4. Thymidine 53-62 vascular endothelial growth factor A Homo sapiens 0-4 10864579-5 2000 VEGF(165) induced a dose-responsive increase in (3)H-thymidine incorporation (25 ng/ml VEGF(165) : 2.3-fold increase; 50 ng/ml : 3.8-fold; 100 ng/ml : 4. Thymidine 53-62 vascular endothelial growth factor A Homo sapiens 87-91 10671553-8 2000 MAPK/ERK kinase inhibition diminished VEGF-, FGF-, and EGF-promoted thymidine incorporation into DNA. Thymidine 68-77 vascular endothelial growth factor A Homo sapiens 38-42 10671553-9 2000 However, blockade of PKC diminished thymidine incorporation into DNA induced by VEGF but not FGF or EGF. Thymidine 36-45 vascular endothelial growth factor A Homo sapiens 80-84 9756915-7 1998 VEGF stimulated the nuclear incorporation of thymidine, reversed 89% by PD 98059 and 72% by Y185F. Thymidine 45-54 vascular endothelial growth factor A Homo sapiens 0-4 10331422-5 1999 VEGF-induced [3H]thymidine uptake was tightly correlated with KDR mRNA and protein concentrations, suggesting that increased KDR expression might account for VEGF"s synergistic activity in the presence of bFGF. Thymidine 17-26 vascular endothelial growth factor A Homo sapiens 0-4 10331422-5 1999 VEGF-induced [3H]thymidine uptake was tightly correlated with KDR mRNA and protein concentrations, suggesting that increased KDR expression might account for VEGF"s synergistic activity in the presence of bFGF. Thymidine 17-26 vascular endothelial growth factor A Homo sapiens 158-162 10698278-2 1999 In the present paper, the involvement of NO in the vascular endothelial growth factor (VEGF), insulin or leptin-stimulated proliferation of human endothelial cells (HUVEC) was measured by [3H]thymidine or bromodeoxyuridine incorporation. Thymidine 192-201 vascular endothelial growth factor A Homo sapiens 87-91 9756915-8 1998 Dominant negative SEK-1 or JNK-1 also significantly reduced VEGF-stimulated thymidine incorporation. Thymidine 76-85 vascular endothelial growth factor A Homo sapiens 60-64 9393975-6 1997 Inhibiting the VEGF-induced activation of ERK with PD098059 did not influence actin organization or cell migration but totally inhibited the VEGF-induced incorporation of thymidine into DNA. Thymidine 171-180 vascular endothelial growth factor A Homo sapiens 15-19 9393975-6 1997 Inhibiting the VEGF-induced activation of ERK with PD098059 did not influence actin organization or cell migration but totally inhibited the VEGF-induced incorporation of thymidine into DNA. Thymidine 171-180 vascular endothelial growth factor A Homo sapiens 141-145 9277477-6 1997 Hypoxia conditioned media from MVSMCs caused human umbilical vein endothelial cells to increase [3H]thymidine incorporation by twofold, an effect that was blocked in a dose-dependent manner by anti-human VEGF antibody. Thymidine 100-109 vascular endothelial growth factor A Homo sapiens 204-208 9201024-8 1997 DNA synthesis, measured by thymidine incorporation, was increased 4-fold compared with control, an effect that was blocked by a neutralizing anti-VEGF antibody. Thymidine 27-36 vascular endothelial growth factor A Homo sapiens 146-150 8755661-2 1996 By measuring thymidine uptake, we found that TNF-alpha blocked a 2.3-fold increase in DNA synthesis induced by VEGF in human endothelial cells. Thymidine 13-22 vascular endothelial growth factor A Homo sapiens 111-115 8840857-5 1996 Furthermore, the susceptibility for VEGF-induced mitogenicity was enhanced under hypoxic conditions as shown by [3H]-thymidine incorporation assay. Thymidine 117-126 vascular endothelial growth factor A Homo sapiens 36-40 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Thymidine 201-210 vascular endothelial growth factor A Homo sapiens 92-96 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Thymidine 201-210 vascular endothelial growth factor A Homo sapiens 147-151 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Thymidine 201-210 vascular endothelial growth factor A Homo sapiens 147-151 24142467-5 2013 [(3)H]Thymidine incorporation assay revealed enhanced porcine pulmonary artery endothelial cell proliferation in response to IL-1beta, VEGF and PlGF, and this mitogenic effect was not influenced via the NO pathway. Thymidine 6-15 vascular endothelial growth factor A Homo sapiens 135-139 29745737-1 2018 INTRODUCTION: TAS102 is an oral thymidine-based nucleoside analog that has been approved for the treatment of patients with metastatic colorectal cancer (mCRC) previously treated with, or not candidates for, available therapies including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-vascular endothelial growth factor (VEGF) agents and, if RAS wild-type, anti-epidermal growth factor receptor (EGFR) therapy. Thymidine 32-41 vascular endothelial growth factor A Homo sapiens 308-347 29745737-1 2018 INTRODUCTION: TAS102 is an oral thymidine-based nucleoside analog that has been approved for the treatment of patients with metastatic colorectal cancer (mCRC) previously treated with, or not candidates for, available therapies including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-vascular endothelial growth factor (VEGF) agents and, if RAS wild-type, anti-epidermal growth factor receptor (EGFR) therapy. Thymidine 32-41 vascular endothelial growth factor A Homo sapiens 349-353 21918971-5 2012 DT-IgG induced EGFR-dependent VEGF internalization, constituting a novel antiangiogenesis mechanism. Thymidine 0-2 vascular endothelial growth factor A Homo sapiens 30-34